ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate
• 英文别名: ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,5-naphthyridine-3-carboxylate
• 化学式: C₁₉H₁₇FN₂O₄
• 分子量: 356.353
• InChiKey: NFILOZULWSDTDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate 生成 GSK364735
  参考文献：
  名称：

  HIV INTEGRASE INHIBITORS

  摘要：

  本发明涉及一种具有HIV整合酶抑制剂特性的化合物，因此可用于抑制HIV复制，预防和/或治疗HIV感染，以及治疗艾滋病和/或ARC。

  公开号：

  US20150225399A1
• 作为产物：
  描述：

  methyl 5-[(4-fluorophenyl)methyl]-3-nitro-2-pyridinecarboxylate 在 AMINOHIPPURATE SODIUM 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 三氟乙酸酐 为溶剂， 生成 ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate
  参考文献：
  名称：

  HIV INTEGRASE INHIBITORS

  摘要：

  本发明具有作为HIV整合酶抑制剂的化合物，因此在抑制HIV复制、预防及/或治疗HIV感染以及治疗艾滋病及/或艾滋病相关综合症方面具有用途。

  公开号：

  US20150225399A1

文献信息

• Hiv Integrase Inhibitors
  申请人：Johns Alvin Brian

  公开号：US20070124152A1

  公开（公告）日：2007-05-31

  The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  本发明涉及一种HIV整合酶抑制剂化合物，因此在抑制HIV复制，预防和/或治疗HIV感染以及治疗艾滋病和/或ARC方面具有用途。
• 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors
  申请人：Johns Brian Alvin

  公开号：US08691991B2

  公开（公告）日：2014-04-08

  The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  本发明涉及能够抑制HIV整合酶的化合物，因此可用于抑制HIV复制，预防和/或治疗HIV感染，以及治疗艾滋病和/或ARC。
• WO2007/19101
  申请人：——

  公开号：——

  公开（公告）日：——
• Naphthyridinone (NTD) integrase inhibitors: N1 Protio and methyl combination substituent effects with C3 amide groups
  作者：Brian A. Johns、Takashi Kawasuji、Jason G. Weatherhead、Eric E. Boros、James B. Thompson、Cecilia S. Koble、Edward P. Garvey、Scott A. Foster、Jerry L. Jeffrey、Tamio Fujiwara

  DOI：10.1016/j.bmcl.2012.11.071

  日期：2013.1

  Substituent effects of a series of N1 protio and methyl naphthyridinone HIV-1 integrase strand-transfer inhibitors has been explored. The effects of combinations of the N1 substituent and C3 amide groups was extensively studied to compare enzyme inhibition, antiviral activity and protein binding effects on potency. The impact of substitution on ligand efficiency was considered and several compounds were advanced into in vivo pharmacokinetic studies ultimately leading to the clinical candidate GSK364735. (C) 2012 Elsevier Ltd. All rights reserved.
• Synthesis and Antiviral Activity of 7-Benzyl-4-hydroxy-1,5-naphthyridin-2(1<i>H</i>)-one HIV Integrase Inhibitors
  作者：Eric E. Boros、Cynthia E. Edwards、Scott A. Foster、Masahiro Fuji、Tamio Fujiwara、Edward P. Garvey、Pamela L. Golden、Richard J. Hazen、Jerry L. Jeffrey、Brian A. Johns、Takashi Kawasuji、Ryuichi Kiyama、Cecilia S. Koble、Noriyuki Kurose、Wayne H. Miller、Angela L. Mote、Hitoshi Murai、Akihiko Sato、James B. Thompson、Mark C. Woodward、Tomokazu Yoshinaga

  DOI：10.1021/jm801404b

  日期：2009.5.14

  The medicinal chemistry and structure-activity relationships for a novel series of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV-integrase inhibitors are disclosed. Substituent effects were evaluated at the N-1, C-3, and 7-benzyl positions of the naphthyridinone ring system. Low nanomolar IC50 values were achieved in an HIV-integrase strand transfer assay with both carboxylic ester and carboxamide groups at C-3. More importantly, several carboxamide congeners showed potent antiviral activity in cellular assays. A 7-benzyl substituent was found to be critical for potent enzyme inhibition, and an N-(2-methoxyethyl)-carboxamide moiety at C-3 significantly reduced plasma protein binding effects in vitro. Pharmacokinetic data in rats for one carboxamide analogue demonstrated oral bioavailability and reasonable in vivo clearance.